Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.

Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma

Atezolizumab + Bevacizumab in Treatment-Naive mRCC

Sunitinib Before Cytoreductive Nephrectomy in mRCC

CABOSUN: Upfront Use of Cabozantinib for mRCC

CheckMate-214: Nivolumab/Ipilimumab for mRCC?

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

Dr. Welling on the Efficacy of Nivolumab in HCC

Jyoti D. Patel, MD, discusses ongoing research investigating immunotherapy in combination with chemotherapy for patients with NSCLC.

Emerging Data Show Promise With Immunotherapy Combos in NSCLC

Philip D. Bonomi, MD, discusses some of the known biomarkers in non-small cell lung cancer (NSCLC), the utilization of PD-L1, and other testing modalities.

Standard Biopsies Retain Significant Role in Lung Cancer Care

Brant Inman, MD, discusses the biology of bladder cancer, the evolving role of checkpoint inhibitors, and the future of chemotherapy in the disease. 

Expert Highlights Biological Advancements in Bladder Cancer Field

HR+ Breast Cancer: Updated Results From MONARCH Trials 

Abemaciclib's Value in Treating HR+ Breast Cancer  

HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3 

HR+ Breast Cancer: Resistance to Primary Therapy 

Factors in Deciding Treatment for HR+ Breast Cancer 

Heterogeneity of Metastatic HR+ Breast Cancer

Understanding Abemaciclib: A New CDK4/6 Inhibitor

CDK4/6 Inhibitor Combinations for HR+ mBC 

ER+/HER2+ Metastatic Breast Cancer

Future Directions: CDK4/6 Inhibitors in Breast Cancer

Treatment Selection for HR+ mBC

Immuno-Oncology

Immuno-Oncology | Specialty